<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2" xml:lang="en">
    <front>
        <journal-meta>
            <journal-id journal-id-type="pmc">F1000Research</journal-id>
            <journal-title-group>
                <journal-title>F1000Research</journal-title>
            </journal-title-group>
            <issn pub-type="epub">2046-1402</issn>
            <publisher>
                <publisher-name>F1000 Research Limited</publisher-name>
                <publisher-loc>London, UK</publisher-loc>
            </publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="doi">10.12688/f1000research.146862.1</article-id>
            <article-categories>
                <subj-group subj-group-type="heading">
                    <subject>Research Article</subject>
                </subj-group>
                <subj-group>
                    <subject>Articles</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Molecular docking and dynamics studies to identify novel active compounds targeting potential breast cancer receptor proteins from an indigenous herb 
                    <italic>Euphorbia thymifolia</italic> Linn</article-title>
                <fn-group content-type="pub-status">
                    <fn>
                        <p>[version 1; peer review: 1 approved with reservations]</p>
                    </fn>
                </fn-group>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Kumblekar</surname>
                        <given-names>Vasavi</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Data Curation</role>
                    <role content-type="http://credit.niso.org/">Formal Analysis</role>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Validation</role>
                    <role content-type="http://credit.niso.org/">Visualization</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <uri content-type="orcid">https://orcid.org/0000-0001-9580-8907</uri>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                    <name>
                        <surname>Kumarchandra</surname>
                        <given-names>Reshma</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Project Administration</role>
                    <role content-type="http://credit.niso.org/">Resources</role>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Visualization</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <uri content-type="orcid">https://orcid.org/0000-0001-8903-0094</uri>
                    <xref ref-type="corresp" rid="c1">a</xref>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Ranganath Pai</surname>
                        <given-names>K Sreedhara</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Project Administration</role>
                    <role content-type="http://credit.niso.org/">Resources</role>
                    <role content-type="http://credit.niso.org/">Software</role>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <uri content-type="orcid">https://orcid.org/0000-0002-2017-9533</uri>
                    <xref ref-type="aff" rid="a2">2</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>K</surname>
                        <given-names>ShamaPrasada</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Project Administration</role>
                    <role content-type="http://credit.niso.org/">Resources</role>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <uri content-type="orcid">https://orcid.org/0000-0002-4158-3893</uri>
                    <xref ref-type="aff" rid="a3">3</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Manandhar</surname>
                        <given-names>Suman</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Data Curation</role>
                    <role content-type="http://credit.niso.org/">Resources</role>
                    <role content-type="http://credit.niso.org/">Software</role>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Validation</role>
                    <role content-type="http://credit.niso.org/">Visualization</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <uri content-type="orcid">https://orcid.org/0000-0002-6562-4047</uri>
                    <xref ref-type="aff" rid="a2">2</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Shastry</surname>
                        <given-names>Rajeshwari</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Project Administration</role>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a4">4</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Rai</surname>
                        <given-names>Sharada</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Project Administration</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a5">5</xref>
                </contrib>
                <aff id="a1">
                    <label>1</label>Department of Biochemistry, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India</aff>
                <aff id="a2">
                    <label>2</label>Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Acaedemy of Higher Education, Manipal, Karnataka, 576104, India</aff>
                <aff id="a3">
                    <label>3</label>Department of Cell and Molecular Biology, Manipal School of Life Science, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India</aff>
                <aff id="a4">
                    <label>4</label>Department of Pharmacology, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India</aff>
                <aff id="a5">
                    <label>5</label>Department of Pathology, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India</aff>
            </contrib-group>
            <author-notes>
                <corresp id="c1">
                    <label>a</label>
                    <email xlink:href="mailto:reshma.kc@manipal.edu">reshma.kc@manipal.edu</email>
                </corresp>
                <fn fn-type="conflict">
                    <p>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>25</day>
                <month>4</month>
                <year>2024</year>
            </pub-date>
            <pub-date pub-type="collection">
                <year>2024</year>
            </pub-date>
            <volume>13</volume>
            <elocation-id>385</elocation-id>
            <history>
                <date date-type="accepted">
                    <day>4</day>
                    <month>4</month>
                    <year>2024</year>
                </date>
            </history>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2024 Kumblekar V et al.</copyright-statement>
                <copyright-year>2024</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <self-uri content-type="pdf" xlink:href="https://f1000research.com/articles/13-385/pdf"/>
            <abstract>
                <sec>
                    <title>Background</title>
                    <p>Breast cancer has become the most prevalent disease and its incidence has almost doubled in the Indian population. This increased burden demands new targeted therapies with novel compounds either synthetically produced or derived from indigenous plants, which could be a promising approach for the development of drugs. 
                        <italic toggle="yes">Euphorbia thymifolia</italic> L is a widely growing tropical herb that has been reported to have various ethnopharmacological properties, including anticancer properties. Therefore, the aim of the present study was to screen the phytoconstituents and identify the active compounds present in the methanolic extract of 
                        <italic toggle="yes">E. thymifolia</italic> (ME.ET) as ligands to inhibit potential protein targets implicated in breast cancer using an 
                        <italic toggle="yes">In-silico</italic> approach.</p>
                </sec>
                <sec>
                    <title>Methods</title>
                    <p>ME.ET was subjected to GC-MS analysis to screen the phytoconstituents, and the identified compounds were docked with protein targets such as extracellular signal-regulated kinases (ERK1), a serine/threonine kinase-1(AKT1), human epidermal growth factor 2 (HER2), estrogen receptor (ER), maternal embryonic leucine zipper kinase (MELK), polo-like kinase-1(PLK1), and protein tyrosine kinase (PTK6). Compounds with good docking scores were further subjected to dynamic studies to understand the protein ligand binding stability, ligand pathway calculation, and molecular mechanics energies combined with Poisson-Boltzmann (MM/PBSA) calculations using the Schrodinger suite.</p>
                </sec>
                <sec>
                    <title>Results</title>
                    <p>GC-MS analysis revealed the presence of 245 phytoconstituents, 219 of which were unique. When subjected to docking, these phytocompounds, namely 3,6,9,12-tetraoxatetradecane-1,14-diyl dibenzoate (TTDB) and succinic acid, 2-(dimethylamino) ethyl 4-isopropylphenyl ester (SADPE), showed good docking scores. Molecular dynamics studies showed a high affinity and low binding energy for TTDB with HER2, ERK1, and SADPE with ER.</p>
                </sec>
                <sec>
                    <title>Conclusions</title>
                    <p>Hence, in this study, we identified two lead compounds in 
                        <italic toggle="yes">E.thymifolia</italic> linn. Further 
                        <italic toggle="yes">invitro</italic> and 
                        <italic toggle="yes">invivo</italic> anticancer studies can be performed to confirm these results and to understand the molecular mechanism by which they exhibit anticancer activity against breast cancer.</p>
                </sec>
            </abstract>
            <kwd-group kwd-group-type="author">
                <kwd>Euphorbia thymifolia</kwd>
                <kwd>phytoconstituents</kwd>
                <kwd>breast cancer</kwd>
                <kwd>anti-cancer activity</kwd>
                <kwd>molecular docking</kwd>
                <kwd>molecular dynamics</kwd>
                <kwd>breast cancer receptor proteins</kwd>
                <kwd>lead compounds.</kwd>
            </kwd-group>
            <funding-group>
                <funding-statement>The author(s) declared that no grants were involved in supporting this work.</funding-statement>
            </funding-group>
        </article-meta>
    </front>
    <body>
        <sec id="sec5" sec-type="intro">
            <title>Introduction</title>
            <p>Breast cancer is the most common and serious disease among women worldwide, affecting their health and socioeconomic status. The incidence of breast cancer has significantly increased and almost doubled compared to the previous decade, with up to 25.8 per 100,000 women among the Indian population. The incidence of breast cancer is higher in younger women and tends to be more aggressive owing to the molecular complexity of the tumor microenvironment (
                <xref ref-type="bibr" rid="ref20">Malvia et al. 2017</xref>). The treatment strategy for breast cancer depends on its subtype and is based on the presence or absence of estrogen (ER), progesterone (PR), and human epidermal growth factor 2 (HER 2) receptors (
                <xref ref-type="bibr" rid="ref31">Waks and Winer 2019</xref>). Tumors with hormone receptor-positive subtypes receive endocrine therapy or targeted antibody treatment; however, triple-negative breast cancer is one of the most aggressive types of breast cancer, with a high recurrence rate, making it the most difficult to treat (
                <xref ref-type="bibr" rid="ref25">Palma et al. 2015</xref>). Targeted therapy with anticancer agents in combination with immunotherapy is one of the treatment strategies for TNBC. However, there is a need for new and efficient compounds to target the proteins implicated in the tumorigenesis of TNBC (
                <xref ref-type="bibr" rid="ref6">Chang-Qing et al. 2020</xref>).</p>
            <p>Targeting cell surface protein receptors can be an effective way to target malignant cells. Overexpression of the cell surface receptor HER2 proteins has been observed in patients diagnosed with invasive HER2 + breast cancer. It plays an important role in the growth and differentiation of epithelial cells (
                <xref ref-type="bibr" rid="ref33">Yousuf et al. 2017</xref>). HER2/EGFR triggers one of the major signalling pathways which involves PI3 kinase, Ras-Raf-MAPK pathway involved in cell survival, proliferation, migration and angiogenesis (
                <xref ref-type="bibr" rid="ref3">Balz et al. 2012</xref>). The estrogen receptor is another important target protein involved in the cross-talk between other signalling pathways and is implicated in the resistance to hormonal treatments in ER-positive breast cancer patients (
                <xref ref-type="bibr" rid="ref34">Zhang et al. 2020</xref>). Protein tyrosine kinase (PTK6) is another important protein target associated with ER+ BC. Increased PTK6 expression is associated with poor overall survival (
                <xref ref-type="bibr" rid="ref14">Ito et al. 2017</xref>). AKT1, a serine/threonine kinase, also known as protein kinase B and extracellular signal-regulated kinases (ERK1), plays a major role in cell proliferation, differentiation, migration, and anti-apoptotic effects and is overexpressed in TNBC (
                <xref ref-type="bibr" rid="ref21">Martorana et al. 2021</xref>; 
                <xref ref-type="bibr" rid="ref10">Gagliardi et al. 2020</xref>; 
                <xref ref-type="bibr" rid="ref11">Guo et al. 2020</xref>). Maternal embryonic leucine zipper kinase (MELK), another pivotal member of the serine/threonine kinase family, is a cell cycle regulator whose overexpression in BC is associated with poor prognosis (
                <xref ref-type="bibr" rid="ref16">Jiang and Zhang 2013</xref>). Therefore, these proteins were chosen as targets to screen and identify the most active compounds against both hormone receptor-positive BC and TNBC.</p>
            <p>
                <italic toggle="yes">Euphorbia thymifolia</italic> known as laghudhika or choti-dudhi, is a herb traditionally used to treat blood dysentery, inflammation, asthma, and stomach pain (
                <xref ref-type="bibr" rid="ref23">Nadkarni and Nadkarni 2007</xref>). This herb has been reported to have antimicrobial, antidiabetic, antiarthritic, antiviral, and anti-inflammatory effects (
                <xref ref-type="bibr" rid="ref19">Mali and Panchal, 2013</xref>). However, the anticancer activity of this compound has not yet been reported so far (
                <xref ref-type="bibr" rid="ref29">Salehi et al. 2019</xref>). Thus, we have studied and reported the anticancer activity of the methanolic extract of 
                <italic toggle="yes">E. thymifolia</italic> for the first time in our previous study.</p>
            <p>Identification of the active compounds responsible for anticancer activity by traditional methods such as bioactivity-guided fractionation is a very elaborate, time-consuming, and laborious method. Recent advances in simulation technology have provided scope for basic in 
                <italic toggle="yes">In silico</italic> studies, which are reliable and efficient for the identification of active compounds (
                <xref ref-type="bibr" rid="ref17">Kumari 
                    <italic toggle="yes">et al</italic>. 2014</xref>). Hence, we screened and analyzed all the phytocompounds identified in the GC-MS analysis of the methanolic extract of 
                <italic toggle="yes">E.thymifolia</italic> using a structure-based virtual screening 
                <italic toggle="yes">in silico</italic> approach to identify potential targets implicated in breast cancer (
                <xref ref-type="bibr" rid="ref26">Pinzi and Rastelli 2019</xref>; 
                <xref ref-type="bibr" rid="ref12">Herrera-Calderon et al. 2020</xref>).</p>
            <sec id="sec6">
                <title>Objectives</title>
                <p>Screening and identification of the active components of 
                    <italic toggle="yes">Euphorbia thymifolia</italic> and identifying their potential targets implicated in breast cancer through Insilico approach.</p>
            </sec>
        </sec>
        <sec id="sec7" sec-type="methods">
            <title>Methods</title>
            <sec id="sec8">
                <title>Study design</title>
                <p>Plant material collection and extract preparation by cold maceration method, GCMS analysis, Insilico molecular docking and molecular dynamics study.</p>
            </sec>
            <sec id="sec9">
                <title>Study setting - Plant material collection and extraction</title>
                <p>The aerial parts of 
                    <italic toggle="yes">Euphorbia thymifolia</italic> L. were procured from the uncultivated areas of the Udupi District from April to June. The plant material was identified and authenticated by taxonomist Dr. K. Gopalakrishna Bhat, Professor of Botany (Rtd.) Poorna Prajna College, Udupi, The plant sample was deposited in the Herbarium of the Department of Pharmacognosy, Manipal College of Pharmaceutical Sciences. (Herbarium Voucher no: PP624) The aerial parts of 
                    <italic toggle="yes">Euphorbia thymifolia</italic> L. were collected, washed thoroughly and carefully with distilled water to remove all the soil and debris. The plant material was shade-dried at room temperature for 15 d until it was dry and crisp. After drying the shoots of 
                    <italic toggle="yes">E. thymifolia</italic> L., they were powdered and stored at 4&#x00b0;C.</p>
            </sec>
            <sec id="sec10">
                <title>Methanolic extract by cold maceration method</title>
                <p>The crude extract (10% w/v) 35 g in 350 ml was prepared by cold maceration as described by Abubakar et al using methanol procured from NICE Chemicals Private Limited (MI2037; B.no 103168) as the solvent for 72 h with intermittent shaking at room temperature. The extracts were then filtered through Whatman No. 1 filter paper. The clear extracts were concentrated using a rotary vacuum flash evaporator and freeze-dried by lyophilization, a process of drying the extract under controlled temperature and pressure using a lyophilizer. These lyophilized crude extracts were stored at 4&#x00b0;C until further use (
                    <xref ref-type="bibr" rid="ref1">Abubakar and Haque 2020</xref>).</p>
            </sec>
            <sec id="sec11">
                <title>GC-MS analysis</title>
                <p>The composition of the methanolic extract of 
                    <italic toggle="yes">E.thymifolia</italic> was analyzed by GC-MS at Analytical Research &amp; Metallurgical Laboratories Pvt. Ltd. Bangalore, India.</p>
            </sec>
            <sec id="sec12">
                <title>In silico methodology: Selection of the lead compound by Molecular docking</title>
                <p>Molecular docking was performed using 
                    <ext-link ext-link-type="uri" xlink:href="https://newsite.schrodinger.com/platform/products/glide/">Schrodinger</ext-link> suite to select the best protein-ligand complex. Commercial 
                    <ext-link ext-link-type="uri" xlink:href="https://newsite.schrodinger.com/platform/products/maestro/">Maestro software</ext-link> version 11.8 (OPLS3e force field) was utilized for all the simulation studies. 
                    <ext-link ext-link-type="uri" xlink:href="https://newsite.schrodinger.com/life-science/learn/white-papers/protein-preparation-wizard/">Protein preparation wizard</ext-link> was used for preparation of protein using the panel review, modify, and refine modules where the side chains and residues were filled, and water molecules beyond 3 &#x00c5; were removed. 
                    <ext-link ext-link-type="uri" xlink:href="https://newsite.schrodinger.com/platform/products/glide/">GLIDE</ext-link> panel was used for receptor-grid generation to create a grid and locate the receptor at the binding site for the ligands to be docked. The size of the grid box generated at the inbound ligand site for each protein was 10 &#x00d7; 10 &#x00d7; 10 &#x00c5; (
                    <xref ref-type="bibr" rid="ref27">Rathi et al. 2019</xref>).</p>
                <p>The crystal structures of the proteins were retrieved from the Protein Data Bank (
                    <xref ref-type="bibr" rid="ref4">Berman et al. 2000</xref>). ERK1 (Protein Data Bank ID: 
                    <ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/4QTB">4QTB</ext-link>, Crystallographic precision of the PDB: 1.40 &#x00c5;) bound to a piperazine-phenyl-pyrimidine derivative (
                    <xref ref-type="bibr" rid="ref5">Chaikuad et al. 2014</xref>); AKT (Protein Data Bank ID: 
                    <ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/4EKL">4EKL</ext-link>, Crystallographic precision of the PDB: 2.00 &#x00c5;) with an ATP site inhibitor which is a piperazine- pyrimidine derivative ligand (
                    <xref ref-type="bibr" rid="ref18">Lin et al. 2012</xref>); EGFR/HER2 (Protein Data Bank ID: 
                    <ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/1XKK">1XKK</ext-link>, Crystallographic precision of the PDB: 2.40 &#x00c5;) with bound ligand Lapatinib is a tyrosine kinase inhibitor in clinical development for cancer (
                    <xref ref-type="bibr" rid="ref32">Wood et al. 2004</xref>); ER (Protein Data Bank ID: 
                    <ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/2IOG">2IOG</ext-link>, Crystallographic precision of the PDB: 1.60 &#x00c5;) with indole ligand (
                    <xref ref-type="bibr" rid="ref8">Dykstra et al. 2007</xref>); The crystal structure of MELK (PDB ID: 
                    <ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/5K00">5K00</ext-link>, Crystallographic precision of the PDB: 1.77 &#x00c5;) with a ligand which is an amide derivative (
                    <xref ref-type="bibr" rid="ref7">Chen et al. 2017</xref>); Crystal structure of PLK1 (PDB ID: 
                    <ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/4J52">4J52</ext-link>, Crystallographic precision of the PDB: 2.30 &#x00c5;) with pyrimidodiazepinone as ligand (
                    <xref ref-type="bibr" rid="ref24">Nie et al. 2013</xref>), and Crystal structure of PTK6 (PDB ID: 
                    <ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/5H2U">5H2U</ext-link>,Crystallographic precision of the PDB: 2.24 &#x00c5;) with ligand Dasatinib (
                    <xref ref-type="bibr" rid="ref30">Thakur et al. 2017</xref>).</p>
                <p>The structures of all 219 phytocompounds were either retrieved from 
                    <ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/">PubChem</ext-link> or derived using 
                    <ext-link ext-link-type="uri" xlink:href="https://en.freedownloadmanager.org/Windows-PC/ChemDraw-Pro.html">Chem-Draw</ext-link> software. These 219 ligands were imported into maestro and &#x201c;
                    <ext-link ext-link-type="uri" xlink:href="https://newsite.schrodinger.com/platform/products/ligprep/">LIGPREP</ext-link>&#x201d; panel was utilized for ligand preparation (
                    <xref ref-type="bibr" rid="ref27">Rathi et al. 2019</xref>). Docking was performed using the Maestro Glide Module. Initially, all ligands were docked in standard precision (SP) mode, followed by extra precision (XP) mode to obtain a ligand docking XP score (
                    <xref ref-type="bibr" rid="ref9">Elokely and Doerksen 2013</xref>).</p>
            </sec>
            <sec id="sec13">
                <title>Free ligand binding energy calculation by Maestro (MM-GBSA)</title>
                <p>All XP docking files corresponding to each phytocompound and the seven proteins were then subjected to MM-GBSA free ligand energy calculation using the PRIME module to understand the binding energy of the target protein listed above with all 219 phytocompounds. (
                    <xref ref-type="bibr" rid="ref22">Ignjatovi&#x0107; et al. 2016</xref>).</p>
            </sec>
            <sec id="sec14">
                <title>Molecular dynamic (MD) simulations</title>
                <p>To determine the protein ligand stability under the simulated physiological environment, the 
                    <ext-link ext-link-type="uri" xlink:href="https://newsite.schrodinger.com/platform/products/ms-desmond/">DESMOND</ext-link> panel of Maestro was used for the MD simulation assessment, which was executed on HER2 (1XKK), ERK1 (4QTB) with 3,6,9,12-tetraoxatetradecane-1,14-diyl dibenzoate (TTDB) (molecular formula: C24H30O8), and ER(2IOG) with succinic acid, 2-(dimethylamino) ethyl 4-isopropylphenyl ester (SADPE) (molecular formula: C17H25NO4) for 100 ns using the XP docking file. Three steps, namely the system builder, minimization, and MD simulation, were involved in this process. A predefined simple point charge model (SPC) was used to create an orthorhombic boundary for the XP docked complex of TTDB with 1XKK, 4QTB, and 2IOG with SADPE. The charges were neutralized, where three positive charges were neutralized by the addition of three chloride ions, and one negative charge was neutralized by one sodium ion. An isothermal&#x2013;isobaric (NPT) ensemble with a constant temperature of 300 K and pressure of 1 bar was maintained throughout the simulation for 100ns. To determine the stability of the complex, the Root Mean Square Deviation (RMSD) was analyzed along with the protein&#x2013;ligand contact timeline and covalent/non-covalent interactions (
                    <xref ref-type="bibr" rid="ref15">Ivanova et al. 2018</xref>).</p>
            </sec>
        </sec>
        <sec id="sec15" sec-type="results">
            <title>Results</title>
            <sec id="sec16">
                <title>GCMS analysis</title>
                <p>GC-MS analysis of the methanolic extract of 
                    <italic toggle="yes">E.thymifolia</italic> showed 23 prominent peaks, with each of the retention time peaks having several hits comprising a total of 245 hits, as shown in Supplemental Data File 1. Each of these hits was recognized by comparing their retention time peak, peak area (%), and height to those of the already known compounds identified by the National Institute of Standards and Technology (NIST) library. Of the 245 phytocompounds, duplicates were removed and 219 unique compounds were identified in the methanolic extract of 
                    <italic toggle="yes">E.thymifolia.</italic> The identified phytocompounds were organic acids, phenyl esters, hydrocarbons, saturated and unsaturated cyclic compounds, and fatty acids.</p>
            </sec>
            <sec id="sec17">
                <title>Molecular docking score and binding energy</title>
                <p>The results of XP molecular docking using GLIDE were as follows: All 219 ligands with each of the seven proteins were comprehensively analyzed with their docking scores and amino acid interactions. The ligands that showed good interaction with most of the proteins were 3,6,9,12-tetraoxatetradecane-1,14-diyl dibenzoate (TTDB), succinic acid, and 2-(dimethylamino) ethyl 4-isopropylphenyl ester (SADPE), as shown in 
                    <xref ref-type="table" rid="T1">Table 1</xref>. TTDB showed very good interaction with two proteins, namely 1XKK and 4QTB, with docking scores: MMGBSA &#x0394;G binding energies of -8.627, -65.22 kcal/mol and -10.112 and -71.103 kcal/mol with two types of non&#x2013;covalent interactions, respectively. Similarly, 2IOG with SADPE exhibited a docking score of -8.865 and MMGBSA &#x0394;G binding energy of -45.94 kcal/mol with two types of non-covalent interactions.</p>
                <table-wrap id="T1" orientation="portrait" position="float">
                    <label>Table 1. </label>
                    <caption>
                        <title>Summary of the Docking results of the ligands chosen.</title>
                    </caption>
                    <table content-type="article-table" frame="hsides">
                        <thead>
                            <tr>
                                <th align="left" colspan="1" rowspan="1" valign="top">Name and structure of the ligand</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Target proteins with PDB ID</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">XP GScore</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">MMGBSA &#x0394;G Binding energies in kCal/mol</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="2" valign="top">1. 3,6,9,12-tetraoxatetradecane-1,14-diyl dibenzoate (TTDB)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">ERK 1 (4QTB)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-10.112</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-71.103</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">EGFR/HER2 (1XKK)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.6272</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-65.22</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">2. Succinic acid, 2-(dimethylamino) ethyl 4-isopropylphenyl ester (SADPE)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">ER (2IOG)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.84</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-45.94</td>
                            </tr>
                        </tbody>
                    </table>
                </table-wrap>
            </sec>
            <sec id="sec18">
                <title>Protein-ligand interactions</title>
                <p>The amino acid residue Lys745 of the 1XKK protein showed a strong hydrogen bond and Phe856 showed pi-pi stacking with TTDB. Lys 71 and Met 125 of the protein 4QTB interacted with the oxy- group of TTDB. The amino acid residue Lys531 of 2IOG showed a hydrogen bond, and Trp383 showed pi-cation interactions with the ligand SADPE, as illustrated in 
                    <xref ref-type="table" rid="T2">Table 2</xref>. Hydrogen bond formation between a ligand and a protein plays a crucial role in drug design. Furthermore, the XP file obtained was subjected to the Prime MM-GBSA method to evaluate the binding affinity more accurately. The calculated binding energies (MM-GBSA &#x0394;G) for 1XKK and 4QTB with the TTDB complex were &#x2212; -65.228 kcal/mol and -71.103 kcal/mol respectively, and that of 2IOG with SADPE was -45.945 kcal/mol.</p>
                <table-wrap id="T2" orientation="portrait" position="float">
                    <label>Table 2. </label>
                    <caption>
                        <title>Protein-ligand interaction diagram.</title>
                    </caption>
                    <table content-type="article-table" frame="hsides">
                        <thead>
                            <tr>
                                <th align="left" colspan="1" rowspan="1" valign="top">Protein-ligand interaction diagram</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Amino acid residues involved in the interaction</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">

                                    <inline-graphic xlink:href="https://f1000research-files.f1000.com/manuscripts/160986/678b8476-6263-431f-a7e5-e78b9c9c3002_gra1.gif"/>
                                </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <bold>1XKK with TTDB:</bold> Hydrogen bond with Lys745
                                    <break/>Pi-Pi stacking with Phe856</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">

                                    <inline-graphic xlink:href="https://f1000research-files.f1000.com/manuscripts/160986/678b8476-6263-431f-a7e5-e78b9c9c3002_gra2.gif"/>
                                </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <bold>4QTB with TTDB:</bold> Hydrogen bonds with Lys71 and Met125</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">

                                    <inline-graphic xlink:href="https://f1000research-files.f1000.com/manuscripts/160986/678b8476-6263-431f-a7e5-e78b9c9c3002_gra3.gif"/>
                                </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <bold>2IOG with SADPE:</bold> Hydrogen bond with Lys531
                                    <break/>Pi-Cation with Trp383</td>
                            </tr>
                        </tbody>
                    </table>
                </table-wrap>
            </sec>
            <sec id="sec19">
                <title>Molecular dynamics</title>
                <p>Furthermore, to understand the interaction between the protein and ligand complex, a molecular dynamics study was performed for 100 ns. The RMSD values obtained were explained to obtain more clarity regarding the binding stability of the docked complexes.</p>
                <p>The RMSD values of HER2 (1XKK) and TTDB were found to be around 4.8 &#x00c5;, 4.0 &#x00c5; respectively. The RMSD plot of both ligand and protein was stable after 20 ns, as shown in 
                    <xref ref-type="fig" rid="f1">Figure 1</xref>. Later, the protein-ligand complex showed varied fluctuations until 50ns and then remained stable for the next 50ns. The molecular dynamics trajectory showed that amino acid residues such as Leu718, Ala 743, and Leu844 were vital before ligand (TTDB) stabilization up to 20 ns. Amino acid residues such as Val726, Leu844, and Phe856 established contacts with the ligand to be crucial hotspots for equilibrium, as shown in 
                    <xref ref-type="fig" rid="f2">Figures 2B</xref> and 
                    <xref ref-type="fig" rid="f3">3</xref>.</p>
                <fig fig-type="figure" id="f1" orientation="portrait" position="float">
                    <label>Figure 1. </label>
                    <caption>
                        <title>Protein-ligand root mean square deviation (RMSD) plot.</title>
                        <p>RMSD plot of TTDB bound to active inhibitor site of HER2 (1XKK).</p>
                    </caption>
                    <graphic id="gr1" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/160986/678b8476-6263-431f-a7e5-e78b9c9c3002_figure1.gif"/>
                </fig>
                <fig fig-type="figure" id="f2" orientation="portrait" position="float">
                    <label>Figure 2. </label>
                    <caption>
                        <title>(A) Protein-ligand contact timeline plot. (B) Total contact timeline plot of TTDB bound to active inhibitory site at HER2 protein (IXKK).</title>
                    </caption>
                    <graphic id="gr2" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/160986/678b8476-6263-431f-a7e5-e78b9c9c3002_figure2.gif"/>
                </fig>
                <fig fig-type="figure" id="f3" orientation="portrait" position="float">
                    <label>Figure 3. </label>
                    <caption>
                        <title>Bar diagram showing various types of interactions established at the amino acid residual sites during HER-2 protein-TTDB ligand simulation.</title>
                    </caption>
                    <graphic id="gr3" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/160986/678b8476-6263-431f-a7e5-e78b9c9c3002_figure3.gif"/>
                </fig>
                <p>To observe the protein-ligand interaction stability of TTDB with 4QTB, the RMSD values of the 4QTB with TTDB was found to be 2.2 &#x00c5; and 2.4 &#x00c5; respectively (
                    <xref ref-type="fig" rid="f4">Figure 4</xref>). This complex exhibited the highest stability throughout the simulation without larger deviations. Amino acid residues, such as Ile 48, Ala 69, Ile73, Arg 84, and Asp 184, were significant in stabilizing the complex until 20 ns. Other amino acid residues, such as Tyr 53, Lys 71, Tyr 81, Met 125, Leu 173, Val 56, and Cys 183, showed strong contact with TTDB and contributed to their strong stabilization for 100 ns. TTDB showed a prominent interaction with ERK (4QTB) (
                    <xref ref-type="fig" rid="f5">Figures 5B</xref> and 
                    <xref ref-type="fig" rid="f6">6 A &amp; B</xref>).</p>
                <fig fig-type="figure" id="f4" orientation="portrait" position="float">
                    <label>Figure 4. </label>
                    <caption>
                        <title>Protein-ligand root mean square deviation (RMSD) plot.</title>
                        <p>RMSD plot of TTDB bound to active inhibitor site of ERK (4QTB).</p>
                    </caption>
                    <graphic id="gr4" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/160986/678b8476-6263-431f-a7e5-e78b9c9c3002_figure4.gif"/>
                </fig>
                <fig fig-type="figure" id="f5" orientation="portrait" position="float">
                    <label>Figure 5. </label>
                    <caption>
                        <title>(A) Protein-ligand contact timeline plot. (B) Total contact timeline plot of TTDB bound to active inhibitory site at ERK 1 protein (4QTB).</title>
                    </caption>
                    <graphic id="gr5" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/160986/678b8476-6263-431f-a7e5-e78b9c9c3002_figure5.gif"/>
                </fig>
                <fig fig-type="figure" id="f6" orientation="portrait" position="float">
                    <label>Figure 6. </label>
                    <caption>
                        <title>(A) Protein interaction diagram. (B) Bar diagram showing various types of interactions established at the amino acid residual sites during ERK-1 protein-TTDB ligand simulation.</title>
                    </caption>
                    <graphic id="gr6" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/160986/678b8476-6263-431f-a7e5-e78b9c9c3002_figure6.gif"/>
                </fig>
                <p>The RMSD values of ER (2IOG) and SADPE were approximately 5.0 &#x00c5;, 4.0 &#x00c5; respectively. The RMSD plot of both ligands and proteins stabilized after 20 ns for some time (
                    <xref ref-type="fig" rid="f7">Figure 7</xref>). Up to 20 ns, amino acid residues such as Thr347, Ala350, Leu 384, Asn532, Cys530, and Lys531 were important prior to ligand stabilization. Subsequently, the amino acid residues Asp351, Leu 387, Phe 404, Trp383, Leu525, and Tyr 526 showed strong interactions with the ligand, which contributed to stabilization (
                    <xref ref-type="fig" rid="f8">Figures 8B</xref> and 
                    <xref ref-type="fig" rid="f9">9</xref>).</p>
                <fig fig-type="figure" id="f7" orientation="portrait" position="float">
                    <label>Figure 7. </label>
                    <caption>
                        <title>Protein-ligand root mean square deviation (RMSD) plot.</title>
                        <p>RMSD plot of SADPE bound to active inhibitor site of ER protein (2IOG).</p>
                    </caption>
                    <graphic id="gr7" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/160986/678b8476-6263-431f-a7e5-e78b9c9c3002_figure7.gif"/>
                </fig>
                <fig fig-type="figure" id="f8" orientation="portrait" position="float">
                    <label>Figure 8. </label>
                    <caption>
                        <title>(A) Protein-ligand contact timeline plot. (B) Total contact timeline plot of SADPE bound to active inhibitory site at ER protein (21OG).</title>
                    </caption>
                    <graphic id="gr8" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/160986/678b8476-6263-431f-a7e5-e78b9c9c3002_figure8.gif"/>
                </fig>
                <fig fig-type="figure" id="f9" orientation="portrait" position="float">
                    <label>Figure 9. </label>
                    <caption>
                        <title>Bar diagram showing various types of interactions established at the amino acid residual sites during ER protein-SADPE ligand simulation.</title>
                    </caption>
                    <graphic id="gr9" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/160986/678b8476-6263-431f-a7e5-e78b9c9c3002_figure9.gif"/>
                </fig>
            </sec>
        </sec>
        <sec id="sec20" sec-type="discussion">
            <title>Discussion</title>
            <p>The phytocompounds were shortlisted based on their docking score, their interaction with more than one protein, and amino acid interactions. A literature search was carried out to investigate whether any of these compounds had anticancer activity. Chloride-substituted phenoxy acetic acid was used for the synthesis of a benzoyl hydrazide derivative, which has been reported to have 
                <italic toggle="yes">in vitro</italic> antimicrobial activity (
                <xref ref-type="bibr" rid="ref2">Al-Ostoot et al. 2019</xref>). To date, no other studies have been reported. TTDB and SADPE showed the highest docking scores against the proteins implicated in the pathogenesis of breast cancer, such as HER2 (IXKK), ERK1 (4QTB), and ER (2IOG). The XP docking results provided insight into the establishment of a strong interaction between a ligand and a protein that contains important amino acid residues. The interaction diagram for all proteins revealed the formation of more than one non-covalent bond, which contributed to the stability of the complex, as described in 
                <xref ref-type="table" rid="T2">Table 2</xref>. The binding affinity calculated for the protein&#x2013;ligand complex supports this statement. From previous literature, RMSD values below 4 &#x00c5; are considered good, which implies minimal protein-ligand fluctuations (
                <xref ref-type="bibr" rid="ref13">Hevener et al. 2009</xref>; 
                <xref ref-type="bibr" rid="ref28">Rao et al. 2021</xref>). In the simulations conducted for 100 ns for TTDB- HER2 &amp; SADPE- ER, stability was established after 20 ns with non-covalent bond interactions. For the entire simulation, HER2 (IXKK) -TTDB had an average of four contacts with a maximum 6 and a minimum of two contacts (
                <xref ref-type="fig" rid="f2">Figure 2A</xref>), and the ER (2IOG)- SADPE complex showed an average of six contacts, with a maximum of 9 and a minimum of three contacts (
                <xref ref-type="fig" rid="f8">Figure 8A</xref>). The ERK1 (4QTB-TTDB) complex showed an average of eight contacts, with a maximum of 12 and a minimum of four contacts, with the highest stability number of interactions when compared to the other two complexes throughout the simulation (
                <xref ref-type="fig" rid="f5">Figure 5A</xref>). In the HER2 (IXKK-TTDB) complex, the majority of contacts were made only by hydrophobic interactions (
                <xref ref-type="fig" rid="f3">Figure 3</xref>). In TTDB- ERK1 complex Lys71 &amp; Met 125 has made contact with the oxy groups for more than 80 % of the time. Other amino acids Tyr81 made a hydrophobic contact with the aromatic ring for approximately 46 % of the time and Cys 183 had hydrogen bonding with oxy group for 30 % of the time, as shown in the ligand-protein contact diagram (
                <xref ref-type="fig" rid="f6">Figure 6A</xref>). In the ER (2IOG-SADPE) complex, Tyr 526 formed a non-covalent interaction due to hydrogen bonding and hydrophobic interactions for most of the contact time (
                <xref ref-type="fig" rid="f9">Figure 9</xref>). In the case of HER2 and ERK1 protein complexes with TTDB, the activity is mainly attributed to the presence of an aromatic ring and multiple Oxy groups present in the ligand. The SADPE activity with the ER protein can be attributed to the presence of oxy groups. From the dynamics study, the ligand TTDB showed a profound interaction with ERK and was highly stable compared to its interaction with HER2. The SADPE-ER complex did not show a significant or stable interaction. Therefore, in our study, we report that TTDB has a greater affinity for binding to the ERK1 protein due to stable interactions, and therefore inhibits the protein. These 
                <italic toggle="yes">in silico</italic> results can be further validated using an in 
                <italic toggle="yes">in-vitro</italic> cytotoxicity assay. Hence, for the first time, we report that the anticancer activity of 
                <italic toggle="yes">E. thymifolia</italic> L. could be attributed to the presence of the active compounds TTDB and SADPE in the crude methanolic extract.</p>
        </sec>
        <sec id="sec21" sec-type="conclusion">
            <title>Conclusion</title>
            <p>Considering the docking score, H bond, binding stability, and contact time between ligand and protein, TTDB and SADPE could be suggested as the active components of the methanolic extract of 
                <italic toggle="yes">E. thymifolia.</italic> Furthermore, these two compounds can be synthesized and tested for their 
                <italic toggle="yes">in vitro</italic> anticancer activity in breast cancer cell lines to confirm the 
                <italic toggle="yes">in silico</italic> results.</p>
        </sec>
    </body>
    <back>
        <sec id="sec25" sec-type="data-availability">
            <title>Data availability</title>
            <sec id="sec26">
                <title>Underlying data</title>
                <p>Dryad: &#x201c;Molecular docking and dynamics studies to identify novel active compounds targeting potential breast cancer receptor proteins from an indigenous herb Euphorbia thymifolia Linn&#x201d; DOI: 
                    <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.rn8pk0pjt">10.5061/dryad.rn8pk0pjt</ext-link> (
                    <xref ref-type="bibr" rid="ref35">Kumblekar et al. 2024</xref>).</p>
                <p>This work was licensed under a 
                    <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0 Universal (CC0 1.0) Public Domain Dedication license</ext-link>.</p>
            </sec>
            <sec id="sec27">
                <title>Reporting guidelines</title>
                <p>Dryad: STROBE checklist for &#x2018;Molecular docking and dynamics studies to identify novel active compounds targeting potential breast cancer receptor proteins from an indigenous herb Euphorbia thymifolia Linn&#x2019; 
                    <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.10906175">https://doi.org/10.5281/zenodo.10906175</ext-link>.</p>
            </sec>
        </sec>
        <sec id="sec22">
            <title>Software availability statement</title>
            <p>Molecular docking as mentioned in the study can also be performed using 
                <ext-link ext-link-type="uri" xlink:href="https://autodock.scripps.edu/download-autodock4/">AutoDock</ext-link> a freely accessible alternative software.</p>
            <sec id="sec28">
                <title>Extended data</title>
                <p>Dryad: Supplementary data file 1 GCMS dataset: 
                    <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.rn8pk0pjt">https://doi.org/10.5061/dryad.rn8pk0pjt</ext-link> (
                    <xref ref-type="bibr" rid="ref35">Kumblekar et al. 2024</xref>).</p>
                <p>This work is licensed under a 
                    <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0 Universal (CC0 1.0) Public Domain Dedication</ext-link> license.</p>
            </sec>
        </sec>
        <ref-list>
            <title>References</title>
            <ref id="ref1">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Abubakar</surname>
                            <given-names>AR</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Haque</surname>
                            <given-names>M</given-names>
                        </name>
</person-group>:
                    <article-title>Preparation of Medicinal Plants: Basic Extraction and Fractionation Procedures for Experimental Purposes.</article-title>
                    <source>

                        <italic toggle="yes">J. Pharm. Bioallied Sci.</italic>
</source>
                    <year>2020</year>;<volume>12</volume>(<issue>1</issue>):<fpage>1</fpage>&#x2013;<lpage>10</lpage>.
                    <pub-id pub-id-type="pmid">32801594</pub-id>
                    <pub-id pub-id-type="doi">10.4103/jpbs.JPBS_175_19</pub-id>
                    <pub-id pub-id-type="pmcid">PMC7398001</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref2">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Al-Ostoot</surname>
                            <given-names>FH</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Mohammed</surname>
                            <given-names>YHE</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Zabiulla Kempaiah</surname>
                            <given-names>AN</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Synthesis, in silico study and in vitro anti-microbial evaluation of some new N-benzoyl-N&#x2032;-[2-(4- chloro-phenoxy)-acetyl]-hydrazides analogs.</article-title>
                    <source>

                        <italic toggle="yes">J. Appl. Pharm. Sci.</italic>
</source>
                    <year>2019</year>;<volume>9</volume>(<issue>07</issue>):<fpage>042</fpage>&#x2013;<lpage>049</lpage>.
                    <pub-id pub-id-type="doi">10.7324/japs.2019.90706</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref3">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Balz</surname>
                            <given-names>LM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Bartkowiak</surname>
                            <given-names>K</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Andreas</surname>
                            <given-names>A</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-&#x03b3;1 signalling in breast cancer cell migration and dissemination.</article-title>
                    <source>

                        <italic toggle="yes">J. Pathol.</italic>
</source>
                    <year>2012</year>;<volume>227</volume>(<issue>2</issue>):<fpage>234</fpage>&#x2013;<lpage>244</lpage>.
                    <pub-id pub-id-type="pmid">22262199</pub-id>
                    <pub-id pub-id-type="doi">10.1002/path.3991</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref4">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Berman</surname>
                            <given-names>HM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Westbrook</surname>
                            <given-names>J</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Feng</surname>
                            <given-names>Z</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>The Protein Data Bank.</article-title>
                    <source>

                        <italic toggle="yes">Nucleic Acids Res.</italic>
</source>
                    <year>2000</year>;<volume>28</volume>(<issue>1</issue>):<fpage>235</fpage>&#x2013;<lpage>242</lpage>.
                    <pub-id pub-id-type="pmid">10592235</pub-id>
                    <pub-id pub-id-type="doi">10.1093/nar/28.1.235</pub-id>
                    <pub-id pub-id-type="pmcid">PMC102472</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref5">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Chaikuad</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Tacconi</surname>
                            <given-names>EM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Zimmer</surname>
                            <given-names>J</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics.</article-title>
                    <source>

                        <italic toggle="yes">Nat. Chem. Biol.</italic>
</source>
                    <year>2014</year>;<volume>10</volume>(<issue>10</issue>):<fpage>853</fpage>&#x2013;<lpage>860</lpage>.
                    <pub-id pub-id-type="pmid">25195011</pub-id>
                    <pub-id pub-id-type="doi">10.1038/nchembio.1629</pub-id>
                    <pub-id pub-id-type="pmcid">PMC4687050</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref6">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Chang-Qing</surname>
                            <given-names>Y</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Jie</surname>
                            <given-names>L</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Shi-Qi</surname>
                            <given-names>Z</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Recent treatment progress of triple negative breast cancer.</article-title>
                    <source>

                        <italic toggle="yes">Prog. Biophys. Mol. Biol.</italic>
</source>
                    <year>2020</year>;<volume>151</volume>:<fpage>40</fpage>&#x2013;<lpage>53</lpage>.
                    <pub-id pub-id-type="doi">10.1016/j.pbiomolbio.2019.11.007</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref7">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Chen</surname>
                            <given-names>X</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Giraldes</surname>
                            <given-names>J</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Sprague</surname>
                            <given-names>ER</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>&#x201c;Addition&#x201d; and &#x201c;Subtraction&#x201d;: Selectivity Design for Type II Maternal Embryonic Leucine Zipper Kinase Inhibitors.</article-title>
                    <source>

                        <italic toggle="yes">J. Med. Chem.</italic>
</source>
                    <year>2017</year>;<volume>60</volume>(<issue>5</issue>):<fpage>2155</fpage>&#x2013;<lpage>2161</lpage>.
                    <pub-id pub-id-type="pmid">28186750</pub-id>
                    <pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b00033</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref8">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Dykstra</surname>
                            <given-names>KD</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Guo</surname>
                            <given-names>L</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Birzin</surname>
                            <given-names>ET</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Estrogen receptor ligands. Part 16: 2-Aryl indoles as highly subtype selective ligands for ER alpha.</article-title>
                    <source>

                        <italic toggle="yes">Bioorg. Med. Chem.</italic>
</source>
                    <year>2007</year>;<volume>17</volume>(<issue>8</issue>):<fpage>2322</fpage>&#x2013;<lpage>2328</lpage>.
                    <pub-id pub-id-type="pmid">17289385</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.bmcl.2007.01.054</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref9">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Elokely</surname>
                            <given-names>KM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Doerksen</surname>
                            <given-names>RJ</given-names>
                        </name>
</person-group>:
                    <article-title>Docking challenge: protein sampling and molecular docking performance.</article-title>
                    <source>

                        <italic toggle="yes">J. Chem. Inf. Model.</italic>
</source>
                    <year>2013</year>;<volume>53</volume>(<issue>8</issue>):<fpage>1934</fpage>&#x2013;<lpage>1945</lpage>.
                    <pub-id pub-id-type="pmid">23530568</pub-id>
                    <pub-id pub-id-type="doi">10.1021/ci400040d</pub-id>
                    <pub-id pub-id-type="pmcid">PMC3755091</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref10">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Gagliardi</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Pitner</surname>
                            <given-names>MK</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Park</surname>
                            <given-names>J</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer.</article-title>
                    <source>

                        <italic toggle="yes">Sci. Rep.</italic>
</source>
                    <year>2020</year>;<volume>10</volume>(<issue>1</issue>):<fpage>8537</fpage>.
                    <pub-id pub-id-type="pmid">32444778</pub-id>
                    <pub-id pub-id-type="doi">10.1038/s41598-020-65250-3</pub-id>
                    <pub-id pub-id-type="pmcid">PMC7244517</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref11">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Guo</surname>
                            <given-names>YJ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Pan</surname>
                            <given-names>WW</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Liu</surname>
                            <given-names>SB</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>ERK/MAPK signalling pathway and tumorigenesis.</article-title>
                    <source>

                        <italic toggle="yes">Exp. Ther. Med.</italic>
</source>
                    <year>2020</year>;<volume>19</volume>(<issue>3</issue>):<fpage>1997</fpage>&#x2013;<lpage>2007</lpage>.
                    <pub-id pub-id-type="pmid">32104259</pub-id>
                    <pub-id pub-id-type="doi">10.3892/etm.2020.8454</pub-id>
                    <pub-id pub-id-type="pmcid">PMC7027163</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref12">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Herrera-Calderon</surname>
                            <given-names>O</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Yepes-P&#x00e9;rez</surname>
                            <given-names>AF</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Quintero-Saumeth</surname>
                            <given-names>J</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Carvacrol: An In Silico Approach of a Candidate Drug on HER2, PI3K&#x03b1;, mTOR, hER-&#x03b1;, PR, and EGFR Receptors in the Breast Cancer.</article-title>
                    <source>

                        <italic toggle="yes">Evid. Based Complement. Alternat. Med.</italic>
</source>
                    <year>2020</year>;<volume>2020</volume>:<fpage>8830612</fpage>&#x2013;<lpage>8830665</lpage>.
                    <pub-id pub-id-type="pmid">33163084</pub-id>
                    <pub-id pub-id-type="doi">10.1155/2020/8830665</pub-id>
                    <pub-id pub-id-type="pmcid">PMC7607278</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref13">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Hevener</surname>
                            <given-names>KE</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Zhao</surname>
                            <given-names>W</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Ball</surname>
                            <given-names>DM</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Validation of molecular docking programs for virtual screening against dihydropteroate synthase.</article-title>
                    <source>

                        <italic toggle="yes">J. Chem. Inf. Model.</italic>
</source>
                    <year>2009</year>;<volume>49</volume>(<issue>2</issue>):<fpage>444</fpage>&#x2013;<lpage>460</lpage>.
                    <pub-id pub-id-type="pmid">19434845</pub-id>
                    <pub-id pub-id-type="doi">10.1021/ci800293n</pub-id>
                    <pub-id pub-id-type="pmcid">PMC2788795</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref14">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Ito</surname>
                            <given-names>K</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Park</surname>
                            <given-names>SH</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Katsyv</surname>
                            <given-names>I</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells.</article-title>
                    <source>

                        <italic toggle="yes">NPJ Breast Cancer.</italic>
</source>
                    <year>2017</year>;<volume>3</volume>:<fpage>45</fpage>.
                    <pub-id pub-id-type="pmid">29167821</pub-id>
                    <pub-id pub-id-type="doi">10.1038/s41523-017-0047-1</pub-id>
                    <pub-id pub-id-type="pmcid">PMC5694002</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref15">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Ivanova</surname>
                            <given-names>L</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Tammiku-Taul</surname>
                            <given-names>J</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Garc&#x00ed;a-Sosa</surname>
                            <given-names>AT</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Molecular Dynamics Simulations of the Interactions between Glial Cell Line-Derived Neurotrophic Factor Family Receptor GFR&#x03b1;1 and Small-Molecule Ligands.</article-title>
                    <source>

                        <italic toggle="yes">ACS Omega.</italic>
</source>
                    <year>2018</year>;<volume>3</volume>(<issue>9</issue>):<fpage>11407</fpage>&#x2013;<lpage>11414</lpage>.
                    <pub-id pub-id-type="pmid">30320260</pub-id>
                    <pub-id pub-id-type="doi">10.1021/acsomega.8b01524</pub-id>
                    <pub-id pub-id-type="pmcid">PMC6173496</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref16">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Jiang</surname>
                            <given-names>P</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Zhang</surname>
                            <given-names>D</given-names>
                        </name>
</person-group>:
                    <article-title>Maternal embryonic leucine zipper kinase (MELK): a novel regulator in cell cycle control, embryonic development, and cancer.</article-title>
                    <source>

                        <italic toggle="yes">Int. J. Mol. Sci.</italic>
</source>
                    <year>2013</year>;<volume>14</volume>(<issue>11</issue>):<fpage>21551</fpage>&#x2013;<lpage>21560</lpage>.
                    <pub-id pub-id-type="pmid">24185907</pub-id>
                    <pub-id pub-id-type="doi">10.3390/ijms141121551</pub-id>
                    <pub-id pub-id-type="pmcid">PMC3856021</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref17">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Kumari</surname>
                            <given-names>R</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Kumar</surname>
                            <given-names>R</given-names>
                        </name>

                        <collab>Open-Source Drug Discovery Consortium</collab>

                        <etal/>
</person-group>:
                    <article-title>g_mmpbsa--a GROMACS tool for high-throughput MM-PBSA calculations.</article-title>
                    <source>

                        <italic toggle="yes">J. Chem. Inf. Model.</italic>
</source>
                    <year>2014</year>;<volume>54</volume>(<issue>7</issue>):<fpage>1951</fpage>&#x2013;<lpage>1962</lpage>.
                    <pub-id pub-id-type="pmid">24850022</pub-id>
                    <pub-id pub-id-type="doi">10.1021/ci500020m</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref35">
                <mixed-citation publication-type="data">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Kumblekar</surname>
                            <given-names>V</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Kumarchandra</surname>
                            <given-names>R</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Ranganath Pai</surname>
                            <given-names>KS</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <data-title>Data from: Molecular docking and dynamics studies to identify novel active compounds targeting potential breast cancer receptor proteins from an indigenous herb Euphorbia thymifolia Linn. Dryad.</data-title>[Dataset].<year>2024</year>.
                    <pub-id pub-id-type="doi">10.5061/dryad.rn8pk0pjt</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref18">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Lin</surname>
                            <given-names>K</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Lin</surname>
                            <given-names>J</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Wu</surname>
                            <given-names>WI</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>An ATP-site on-off switch that restricts phosphatase accessibility of Akt.</article-title>
                    <source>

                        <italic toggle="yes">Sci. Signal.</italic>
</source>
                    <year>2012</year>;<volume>5</volume>(<issue>223</issue>):<fpage>ra37</fpage>.
                    <pub-id pub-id-type="pmid">22569334</pub-id>
                    <pub-id pub-id-type="doi">10.1126/scisignal.2002618</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref19">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Mali</surname>
                            <given-names>PY</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Panchal</surname>
                            <given-names>SS</given-names>
                        </name>
</person-group>:
                    <article-title>A review on phyto-pharmacological potentials of 
                        <italic toggle="yes">Euphorbia thymifolia</italic> L.</article-title>
                    <source>

                        <italic toggle="yes">Anc. Sci. Life.</italic>
</source>
                    <year>2013</year>;<volume>32</volume>(<issue>3</issue>):<fpage>165</fpage>&#x2013;<lpage>172</lpage>.
                    <pub-id pub-id-type="pmid">24501446</pub-id>
                    <pub-id pub-id-type="doi">10.4103/0257-7941.123001</pub-id>
                    <pub-id pub-id-type="pmcid">PMC3902538</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref20">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Malvia</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Bagadi</surname>
                            <given-names>SA</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Dubey</surname>
                            <given-names>US</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Epidemiology of breast cancer in Indian women.</article-title>
                    <source>

                        <italic toggle="yes">Asia Pac. J. Clin. Oncol.</italic>
</source>
                    <year>2017</year>;<volume>13</volume>(<issue>4</issue>):<fpage>289</fpage>&#x2013;<lpage>295</lpage>.
                    <pub-id pub-id-type="doi">10.1111/ajco.12661</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref21">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Martorana</surname>
                            <given-names>F</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Motta</surname>
                            <given-names>G</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Pavone</surname>
                            <given-names>G</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?</article-title>
                    <source>

                        <italic toggle="yes">Front. Pharmacol.</italic>
</source>
                    <year>2021</year>;<volume>12</volume>:<fpage>662232</fpage>.
                    <pub-id pub-id-type="pmid">33995085</pub-id>
                    <pub-id pub-id-type="doi">10.3389/fphar.2021.662232</pub-id>
                    <pub-id pub-id-type="pmcid">PMC8118639</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref22">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Misini Ignjatovi&#x0107;</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Caldararu</surname>
                            <given-names>O</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Dong</surname>
                            <given-names>G</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Binding-affinity predictions of HSP90 in the D3R Grand Challenge 2015 with docking, MM/GBSA, QM/MM, and free-energy simulations.</article-title>
                    <source>

                        <italic toggle="yes">J. Comput. Aided Mol. Des.</italic>
</source>
                    <year>2016</year>;<volume>30</volume>(<issue>9</issue>):<fpage>707</fpage>&#x2013;<lpage>730</lpage>.
                    <pub-id pub-id-type="pmid">27565797</pub-id>
                    <pub-id pub-id-type="doi">10.1007/s10822-016-9942-z</pub-id>
                    <pub-id pub-id-type="pmcid">PMC5078160</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref23">
                <mixed-citation publication-type="book">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Nadkarni</surname>
                            <given-names>KM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Nadkarni</surname>
                            <given-names>AK</given-names>
                        </name>
</person-group>:
                    <source>

                        <italic toggle="yes">Indian Materia Medica.</italic>
</source>
                    <edition>3rd ed.</edition>
                    <publisher-loc>Bombay</publisher-loc>:
                    <publisher-name>Popular Prakashan</publisher-name>;<year>2007</year>;<fpage>529</fpage>.</mixed-citation>
            </ref>
            <ref id="ref24">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Nie</surname>
                            <given-names>Z</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Feher</surname>
                            <given-names>V</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Natala</surname>
                            <given-names>S</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Discovery of TAK-960: an orally available small molecule inhibitor of polo-like kinase 1 (PLK1).</article-title>
                    <source>

                        <italic toggle="yes">Bioorg. Med. Chem. Lett.</italic>
</source>
                    <year>2013</year>;<volume>23</volume>(<issue>12</issue>):<fpage>3662</fpage>&#x2013;<lpage>3666</lpage>.
                    <pub-id pub-id-type="pmid">23664874</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.bmcl.2013.02.083</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref25">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Palma</surname>
                            <given-names>G</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Frasci</surname>
                            <given-names>G</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Chirico</surname>
                            <given-names>A</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Triple negative breast cancer: looking for the missing link between biology and treatments.</article-title>
                    <source>

                        <italic toggle="yes">Oncotarget.</italic>
</source>
                    <year>2015</year>;<volume>6</volume>(<issue>29</issue>):<fpage>26560</fpage>&#x2013;<lpage>26574</lpage>.
                    <pub-id pub-id-type="pmid">26387133</pub-id>
                    <pub-id pub-id-type="doi">10.18632/oncotarget.5306</pub-id>
                    <pub-id pub-id-type="pmcid">PMC4694936</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref26">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Pinzi</surname>
                            <given-names>L</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Rastelli</surname>
                            <given-names>G</given-names>
                        </name>
</person-group>:
                    <article-title>Molecular Docking: Shifting Paradigms in Drug Discovery.</article-title>
                    <source>

                        <italic toggle="yes">Int. J. Mol. Sci.</italic>
</source>
                    <year>2019</year>;<volume>20</volume>(<issue>18</issue>):<fpage>4331</fpage>.
                    <pub-id pub-id-type="pmid">31487867</pub-id>
                    <pub-id pub-id-type="doi">10.3390/ijms20184331</pub-id>
                    <pub-id pub-id-type="pmcid">PMC6769923</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref27">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Rathi</surname>
                            <given-names>E</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Kumar</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Kini</surname>
                            <given-names>SG</given-names>
                        </name>
</person-group>:
                    <article-title>Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.</article-title>
                    <source>

                        <italic toggle="yes">J. Recept. Signal Transduct. Res.</italic>
</source>
                    <year>2019</year>;<volume>39</volume>(<issue>5-6</issue>):<fpage>415</fpage>&#x2013;<lpage>433</lpage>.
                    <pub-id pub-id-type="pmid">31755336</pub-id>
                    <pub-id pub-id-type="doi">10.1080/10799893.2019.1690509</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref28">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Rao</surname>
                            <given-names>V</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Cheruku</surname>
                            <given-names>SP</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Manandhar</surname>
                            <given-names>S</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Restoring chemo-sensitivity to temozolomide via targeted inhibition of poly (ADP-ribose) polymerase-1 by naringin in glioblastoma.</article-title>
                    <source>

                        <italic toggle="yes">Chem. Pap.</italic>
</source>
                    <year>2021</year>;<volume>75</volume>:<fpage>4861</fpage>&#x2013;<lpage>4871</lpage>.
                    <pub-id pub-id-type="doi">10.1007/s11696-021-01700-0</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref29">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Salehi</surname>
                            <given-names>B</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Iriti</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Vitalini</surname>
                            <given-names>S</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Euphorbia-Derived Natural Products with Potential for Use in Health Maintenance.</article-title>
                    <source>

                        <italic toggle="yes">Biomolecules.</italic>
</source>
                    <year>2019</year>;<volume>9</volume>(<issue>8</issue>):<fpage>337</fpage>.
                    <pub-id pub-id-type="pmid">31382529</pub-id>
                    <pub-id pub-id-type="doi">10.3390/biom9080337</pub-id>
                    <pub-id pub-id-type="pmcid">PMC6723572</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref30">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Thakur</surname>
                            <given-names>MK</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Birudukota</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Swaminathan</surname>
                            <given-names>S</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Co-crystal structures of PTK6: With Dasatinib at 2.24 &#x00c5;, with novel imidazo[1,2-a] pyrazin-8-amine derivative inhibitor at 1.70 &#x00c5; resolution.</article-title>
                    <source>

                        <italic toggle="yes">Biochem. Biophys. Res. Commun.</italic>
</source>
                    <year>2017</year>;<volume>482</volume>(<issue>4</issue>):<fpage>1289</fpage>&#x2013;<lpage>1295</lpage>.
                    <pub-id pub-id-type="pmid">27993680</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.bmcl.2011.07.101</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref31">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Waks</surname>
                            <given-names>AG</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Winer</surname>
                            <given-names>EP</given-names>
                        </name>
</person-group>:
                    <article-title>Breast Cancer Treatment: A Review.</article-title>
                    <source>

                        <italic toggle="yes">JAMA.</italic>
</source>
                    <year>2019</year>;<volume>321</volume>(<issue>3</issue>):<fpage>288</fpage>&#x2013;<lpage>300</lpage>.
                    <pub-id pub-id-type="doi">10.1001/jama.2018.19323</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref32">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Wood</surname>
                            <given-names>ER</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Truesdale</surname>
                            <given-names>AT</given-names>
                        </name>

                        <name name-style="western">
                            <surname>McDonald</surname>
                            <given-names>OB</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.</article-title>
                    <source>

                        <italic toggle="yes">Cancer Res.</italic>
</source>
                    <year>2004</year>;<volume>64</volume>(<issue>18</issue>):<fpage>6652</fpage>&#x2013;<lpage>6659</lpage>.
                    <pub-id pub-id-type="pmid">15374980</pub-id>
                    <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-1168</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref33">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Yousuf</surname>
                            <given-names>Z</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Iman</surname>
                            <given-names>K</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Iftikhar</surname>
                            <given-names>N</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Structure-based virtual screening and molecular docking for the identification of potential multi-targeted inhibitors against breast cancer.</article-title>
                    <source>

                        <italic toggle="yes">Breast Cancer (Dove Med Press).</italic>
</source>
                    <year>2017</year>;<volume>9</volume>:<fpage>447</fpage>&#x2013;<lpage>459</lpage>.
                    <pub-id pub-id-type="pmid">28652811</pub-id>
                    <pub-id pub-id-type="doi">10.2147/BCTT.S132074</pub-id>
                    <pub-id pub-id-type="pmcid">PMC5476443</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref34">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Zhang</surname>
                            <given-names>J</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Wang</surname>
                            <given-names>Q</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Wang</surname>
                            <given-names>Q</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Mechanisms of resistance to estrogen receptor modulators in ER+/HER2- advanced breast cancer.</article-title>
                    <source>

                        <italic toggle="yes">Cell. Mol. Life Sci.</italic>
</source>
                    <year>2020</year>;<volume>77</volume>(<issue>4</issue>):<fpage>559</fpage>&#x2013;<lpage>572</lpage>.
                    <pub-id pub-id-type="pmid">31471681</pub-id>
                    <pub-id pub-id-type="doi">10.1007/s00018-019-03281-4</pub-id>
                </mixed-citation>
            </ref>
        </ref-list>
    </back>
    <sub-article article-type="reviewer-report" id="report324470">
        <front-stub>
            <article-id pub-id-type="doi">10.5256/f1000research.160986.r324470</article-id>
            <title-group>
                <article-title>Reviewer response for version 1</article-title>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author">
                    <name>
                        <surname>Math</surname>
                        <given-names>Renukaradhya</given-names>
                    </name>
                    <xref ref-type="aff" rid="r324470a1">1</xref>
                    <role>Referee</role>
                    <uri content-type="orcid">https://orcid.org/0000-0002-6012-7375</uri>
                </contrib>
                <aff id="r324470a1">
                    <label>1</label>Shri Dharmasthala Manjunatheshwara University, Dharwad, India</aff>
            </contrib-group>
            <author-notes>
                <fn fn-type="conflict">
                    <p>
                        <bold>Competing interests: </bold>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>9</day>
                <month>10</month>
                <year>2024</year>
            </pub-date>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2024 Math R</copyright-statement>
                <copyright-year>2024</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <related-article ext-link-type="doi" id="relatedArticleReport324470" related-article-type="peer-reviewed-article" xlink:href="10.12688/f1000research.146862.1"/>
            <custom-meta-group>
                <custom-meta>
                    <meta-name>recommendation</meta-name>
                    <meta-value>approve-with-reservations</meta-value>
                </custom-meta>
            </custom-meta-group>
        </front-stub>
        <body>
            <p>Manuscript entitled &#x201c;Molecular docking and dynamics studies to identify novel active compounds targeting potential breast cancer receptor proteins from an indigenous herb 
                <italic>Euphorbia thymifolia</italic> Linn&#x201d; by Kumblekar et al. is written well. My comments are below,</p>
            <p> </p>
            <p> 
                <bold>1. Abstract (Background)</bold>: author states &#x201c; 
                <italic>Euphorbia thymifolia </italic>L is a widely growing tropical herb that has been reported to have various ethnopharmacological properties, including anticancer properties but further in Introduction section they state &#x201c;However, the anticancer activity of this compound has not yet been reported so far&#x201d; two statements are contradictory. In fact a recent study by Sulaiman C.T. et al 2023 (Ref 1) profiled anti-cancer activity of two Euphorbia species (thymifolia and hirta).</p>
            <p> </p>
            <p> 2.&#x00a0;
                <bold>Introduction section</bold>: author state &#x201c;we have studied and reported the anticancer activity of the methanolic extract of 
                <italic>E. thymifolia </italic>for the first time in our previous study&#x201d; reference is missing!</p>
            <p>Is the work clearly and accurately presented and does it cite the current literature?</p>
            <p>Partly</p>
            <p>If applicable, is the statistical analysis and its interpretation appropriate?</p>
            <p>Not applicable</p>
            <p>Are all the source data underlying the results available to ensure full reproducibility?</p>
            <p>Yes</p>
            <p>Is the study design appropriate and is the work technically sound?</p>
            <p>Yes</p>
            <p>Are the conclusions drawn adequately supported by the results?</p>
            <p>Yes</p>
            <p>Are sufficient details of methods and analysis provided to allow replication by others?</p>
            <p>Yes</p>
            <p>Reviewer Expertise:</p>
            <p>Microbiology, biotechnology and bioinformatics</p>
            <p>I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.</p>
        </body>
        <back>
            <ref-list>
                <title>References</title>
                <ref id="rep-ref-324470-1">
                    <label>1</label>
                    <mixed-citation publication-type="journal">
                        <person-group person-group-type="author"/>:
                        <article-title>Metabolite profiling and anti-cancer activity of two medicinally important Euphorbia species</article-title>.
                        <source>
                            <italic>Medicine in Omics</italic>
                        </source>.<year>2023</year>;<volume>7</volume>:
                        <elocation-id>10.1016/j.meomic.2022.100018</elocation-id>
                        <pub-id pub-id-type="doi">10.1016/j.meomic.2022.100018</pub-id>
                    </mixed-citation>
                </ref>
            </ref-list>
        </back>
        <sub-article article-type="response" id="comment12596-324470">
            <front-stub>
                <contrib-group>
                    <contrib contrib-type="author">
                        <name>
                            <surname>Kumblekar</surname>
                            <given-names>Vasavi</given-names>
                        </name>
                        <aff>Biochemistry, Manipal Academy of Higher Education, Mangalore, Karnataka, India</aff>
                    </contrib>
                </contrib-group>
                <author-notes>
                    <fn fn-type="conflict">
                        <p>
                            <bold>Competing interests: </bold>No competing interests were disclosed.</p>
                    </fn>
                </author-notes>
                <pub-date pub-type="epub">
                    <day>9</day>
                    <month>10</month>
                    <year>2024</year>
                </pub-date>
            </front-stub>
            <body>
                <p>Dear Dr. Renukaradhya Math,&#x00a0;</p>
                <p> Thank you for taking your precious time to review our article and for the critical analysis. We would like to give our clarifications for the queries raised.&#x00a0;</p>
                <p> </p>
                <p> Comment 1. Abstract (Background): author states &#x201c;&#x00a0;
                    <italic>Euphorbia thymifolia&#x00a0;</italic>L is a widely growing tropical herb that has been reported to have various ethnopharmacological properties, including anticancer properties but further in Introduction section they state &#x201c;However, the anticancer activity of this compound has not yet been reported so far&#x201d; two statements are contradictory. In fact a recent study by Sulaiman C.T. et al 2023 (Ref 1) profiled anti-cancer activity of two Euphorbia species (thymifolia and hirta).</p>
                <p> </p>
                <p> Response: We actually meant to state that Euphorbia genus in general has been reported to have various ethnopharmacological properties including anticancer properties. But the species of interest in our study namely 
                    <italic>Euphorbia thymifolia</italic> although was reported to have several ethnopharmacological properties, anticancer property was not reported as per the literature available, when we initiated the project (2019). However we can rectify the statement already mentioned in the manuscript if you permit us to do so.</p>
                <p> </p>
                <p> Comment 2: Introduction section: author state &#x201c;we have studied and reported the anticancer activity of the methanolic extract of&#x00a0;
                    <italic>E. thymifolia&#x00a0;</italic>for the first time in our previous study&#x201d; reference is missing!</p>
                <p> </p>
                <p> Response: We have studied the invitro anticancer activity of the methanolic extract of&#x00a0;
                    <italic>E. thymifolia. </italic>This original article has been communicated to the journal "Jordan Journal of Pharmaceutical Sciences" for possible publication, Hence the reference could not be cited until published.</p>
                <p> </p>
                <p> Requesting you to kindly review the responses and do the needful.</p>
                <p> </p>
                <p> Thanking You,</p>
                <p> Yours Sincerely</p>
                <p> Vasavi K</p>
            </body>
        </sub-article>
    </sub-article>
</article>
